<DOC>
	<DOCNO>NCT00234091</DOCNO>
	<brief_summary>The purpose study determine HIV infect child begin take anti-HIV medication order improve patient quality life survival .</brief_summary>
	<brief_title>When Start Anti-HIV Drugs Children Infected With HIV ( The PREDICT Study )</brief_title>
	<detailed_description>The use highly active antiretroviral therapy ( HAART ) result significant reduction AIDS-related death complication among adults adolescent . However , medical management HIV infect child remain challenge . Access HIV treatment limit early treatment initiation cause serious complication . Since currently cure HIV , balance treat disease maintain quality life must weigh carefully . An evaluation determine appropriate time initiate HAART necessary improve quality life survival HIV infect child . This study last 144 week . All participant CD4 percentage ( CD4 % ) 15 % 24 % randomly assign either receive immediate delay HAART . The HAART regimen consist two nucleoside reverse transcriptase inhibitor , zidovudine lamivudine . In addition , participant also receive either one non-nucleoside reverse transcriptase inhibitor , nevirapine efavirenz , one protease inhibitor , ritonavir-boosted lopinavir nelfinavir . Abacavir replace zidovudine lamivudine participant experience toxicity regimen . Participants immediate treatment arm receive HAART Day 1 study regardless CD4 % . Participants delay treatment arm receive HAART CD4 % fall 15 develop CDC Category C illness . Study visit occur every 4 week first 12 week every 12 week end study . Blood collection , physical exam , medical medication history review occur visit . Adherence , quality life , lipodystrophy assessment occur every 12 week participant HAART . Participants encourage enroll relate substudy examine neurodevelopment HIV infect child .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>HIV1 infect Antiretroviral naive , define never receive antiHIV medication , receive less 7 day , receive prevent mothertochild transmission ( MTCT ) CD4 % 15 24 within 30 day prior study entry CDC pediatric clinical classification A B Parent guardian willing provide inform consent willing follow study procedure requirement Use systemic chemotherapy , immunomodulators , HIV vaccine , immune globulin , interleukin , interferon within 30 day prior study entry Active AIDSdefining illness ( CDC Category C ) within 30 day prior study entry Certain abnormal laboratory value Known kidney disease Known allergy sensitivity study drug Require certain medication Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Treatment Naive</keyword>
	<keyword>Treatment Initiation</keyword>
	<keyword>Infant</keyword>
	<keyword>Preschool Child</keyword>
	<keyword>Child</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>AZT</keyword>
	<keyword>Retrovir</keyword>
	<keyword>3TC</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Epivir</keyword>
	<keyword>Nevirapine</keyword>
	<keyword>NVP</keyword>
	<keyword>Viramune</keyword>
	<keyword>Efavirenz</keyword>
	<keyword>EFV</keyword>
	<keyword>Sustiva</keyword>
	<keyword>Lopinavir/Ritonavir</keyword>
	<keyword>LPV/r</keyword>
	<keyword>Kaletra</keyword>
	<keyword>Nelfinavir</keyword>
	<keyword>NFV</keyword>
	<keyword>Viracept</keyword>
	<keyword>ABC</keyword>
	<keyword>Abacavir</keyword>
	<keyword>Ziagen</keyword>
</DOC>